UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

The New England journal of medicine, 2018-08, Vol.379 (9), p.811-822

2018

Volltextzugriff (PDF)

Structure and ligand of a histone acetyltransferase bromodomain

Nature (London), 1999-06, Vol.399 (6735), p.491-496

1999

Volltextzugriff (PDF)

Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α2 a and Its Individual Positional Isomers

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.504-517

2005

Volltextzugriff (PDF)

Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α2 a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.518-527

2005

Volltextzugriff (PDF)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

Journal of clinical pharmacology, 2022-02, Vol.62 (2), p.232-244

2022

Volltextzugriff (PDF)

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Blood, 2023-11, Vol.142 (Supplement 1), p.1238-1238

2023

Volltextzugriff (PDF)

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Blood, 2024-04, Vol.143 (14), p.1355-1364

2024

Volltextzugriff (PDF)

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.505-505

2023

Volltextzugriff (PDF)

Magic Angle Spinning Nuclear Magnetic Resonance in Solid-Phase Peptide Synthesis

Journal of the American Chemical Society, 1997-10, Vol.119 (43), p.10494-10500

1997

Volltextzugriff (PDF)

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Blood, 2022-11, Vol.140 (Supplement 1), p.457-459

2022

Volltextzugriff (PDF)

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Blood, 2019-11, Vol.134 (Supplement_1), p.2395-2395

2019

Volltextzugriff (PDF)

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Blood, 2017-12, Vol.130 (Suppl_1), p.85-85

2017

Volltextzugriff (PDF)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Blood advances, 2022-12, Vol.6 (24), p.6140-6150

2022

Volltextzugriff (PDF)

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Blood, 2017-12, Vol.130 (Suppl_1), p.89-89

2017

Volltextzugriff (PDF)

The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS9597-TPS9597

2012

Volltextzugriff (PDF)

Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3

Molecular cell, 2001-02, Vol.7 (2), p.387-399

2001

Volltextzugriff (PDF)

Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3: Structural Insights into MKP-3 Activation by ERK2

Molecular cell, 2001-02, Vol.7 (2), p.387-399

2001

Volltextzugriff (PDF)

Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors

Molecular cell, 2000-10, Vol.6 (4), p.921-929

2000

Volltextzugriff (PDF)

Study of Compounds Attached to Solid Supports Using High Resolution Magic Angle Spinning NMR

Current organic chemistry, 1999-03, Vol.3 (2), p.147-169

1999

Volltextzugriff (PDF)

Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α 2 a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.518-527

2005

Volltextzugriff (PDF)

Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α 2 a and Its Individual Positional Isomers

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.504-517

2005

Volltextzugriff (PDF)

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.518-527

2005

Volltextzugriff (PDF)

Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers

Bioconjugate chemistry, 2005-05, Vol.16 (3), p.504-517

2005

Volltextzugriff (PDF)

Monitoring of a three-step solid phase synthesis involving a Heck reaction using magic angle spinning NMR spectroscopy

Tetrahedron, 1996-09, Vol.52 (37), p.12209-12222

1996

Volltextzugriff (PDF)

Letter to the Editor: 1H, 13C and 15N resonance assignments of the SNT PTB domain in complex with FGFR1 peptide

Journal of biomolecular NMR, 2000-12, Vol.18 (4), p.371

2000

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(44)

Sprache

Englisch
(42)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(19)
Humans
(13)
Life Sciences
(9)
Microbiology
(7)
Microbiology And Parasitology
(7)
Virulence
(6)
Anti-Bacterial Agents - Pharmacology
(5)
Bacteriology
(5)
Male
(5)
Models, Molecular
(5)
Pharmacology & Pharmacy
(5)
Animals
(4)
Binding Sites
(4)
Biochemistry & Molecular Biology
(4)
Chemistry
(4)
Microbial Sensitivity Tests
(4)
Molecular Sequence Data
(4)
Nuclear Magnetic Resonance, Biomolecular
(4)
Oxidative Stress
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(7)
Bioconjugate Chemistry
(6)
Molecular Cell
(3)
Annales De Pathologie
(2)
Bmc Microbiology
(2)
Chest
(2)
Gastroenterology
(2)
Journal Of Biomolecular Nmr
(2)
Antimicrobial Agents And Chemotherapy
(1)
Archives Of Microbiology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Structure and ligand of a histone acetyltransferase bromodomain

Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α2 a and Its Individual Positional Isomers

Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α2 a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Magic Angle Spinning Nuclear Magnetic Resonance in Solid-Phase Peptide Synthesis

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS)

Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3

Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3: Structural Insights into MKP-3 Activation by ERK2

Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors

Study of Compounds Attached to Solid Supports Using High Resolution Magic Angle Spinning NMR

Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α 2 a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2

Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α 2 a and Its Individual Positional Isomers

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2

Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers

Monitoring of a three-step solid phase synthesis involving a Heck reaction using magic angle spinning NMR spectroscopy

Letter to the Editor: 1H, 13C and 15N resonance assignments of the SNT PTB domain in complex with FGFR1 peptide

Suchergebnisse filtern